Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. - Wikidata - awgldk - TriplyDB

Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial.

Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial.

http://www.wikidata.org/entity/Q37062357

about

Plant Protease Inhibitors in Therapeutics-Focus on Cancer Therapy Nutraceuticals and Their Potential to Treat Duchenne Muscular Dystrophy: Separating the Credible from the Conjecture Overexpression of lipocalins and pro-inflammatory chemokines and altered methylation of PTGS2 and APC2 in oral squamous cell carcinomas induced in rats by 4-nitroquinoline-1-oxide Visceral hypersensitivity in inflammatory bowel diseases and irritable bowel syndrome: The role of proteases Bowman-Birk inhibitors from legumes as colorectal chemopreventive agents.Interventions for treating oral leukoplakia to prevent oral cancer.Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial.Optimizing biomarkers and endpoints in oral cancer chemoprevention trials.A Bowman-Birk inhibitor induces apoptosis in human breast adenocarcinoma through mitochondrial impairment and oxidative damage following proteasome 20S inhibition Novel Molecular Targets for Chemoprevention in Malignancies of the Head and Neck.Prognostic factors, predictive markers and cancer biology: the triad for successful oral cancer chemoprevention.Potent Antitumor Effects of a Combination of Three Nutraceutical Compounds Chemoprevention of Head and Neck Cancers: Does It Have Only One Face?Integrative care of the patient with head and neck cancer

P2860

Q28071713-E2EFBE78-F5D0-4A51-8C32-E74A75875517 Q28072269-F48ED1F2-0206-4BD5-9706-94A851A8EFF2 Q28543174-F1BFEA8D-FA78-4758-B209-24977B2BE91A Q28818844-9D1E999C-496A-4AD1-B68C-47F64ACB0D4C Q34036615-746373CD-C242-446C-B4E0-87197ACB6731 Q34535749-2D16B1D9-A3C1-4A2E-9893-FC11D4CDEF1E Q36631786-C4FD9284-EFEC-458E-A585-2F419006CDD3 Q36931001-756ABAF9-85F9-49B1-A0FE-FE3339E68C62 Q37164347-4154EE09-9815-4145-94DE-3334928B941E Q38635035-DA7E6EBB-97E0-4606-A915-09E4E63A5250 Q38850128-7A574372-6EEF-44A1-ABF5-BE1EBE7CBEEC Q57169343-93FD338A-87A1-4922-BA95-AB6485F602E5 Q57821380-66171E8B-4B63-4A86-9C05-24EE69C0E3A4 Q58557299-72972FD0-A1B7-4893-ADE8-E0F546C2C9AE

P2860

Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial.

http://www.wikidata.org/entity/Q37062357

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial.

@en

Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial.

@nl

type

label

Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial.

@en

Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial.

@nl

prefLabel

Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial.

@en

Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial.

@nl

P1433

Q37062357-4C8AA17D-6C91-4F21-99A0-C13ACB500774

P1476

Q37062357-2F6BC59E-3CB0-4A5E-AE19-41472D459C10

P2093

Q37062357-1E7C2AB1-E30A-4CE6-BCBE-2630EE3A8C58

Q37062357-28691054-4C01-4822-9827-B9B10DEFCD33

Q37062357-33F5B342-6269-4521-84C4-DFE148DDBAC6

Q37062357-3F4A40DE-D14C-47F6-94A3-091251BC3DA2

Q37062357-5ACCD8D1-5752-4AC9-B36D-41FA7161F737

Q37062357-60046E44-0CDA-410B-BE11-3213E41E3A7D

Q37062357-76311306-B884-4CE6-A59E-9131446E6C30

Q37062357-920D5035-7784-4D58-96E2-95C81E635875

Q37062357-96CA6BCB-F84E-454D-8BBE-3503311A5DFB

Q37062357-A5A9609C-67F5-4623-AA82-EFDBE9123947

P2860

Q37062357-08A08F40-2C88-41E3-9651-820DB351CF6C

Q37062357-1159B0A5-DB4C-438B-B722-4B4C4F612EAA

Q37062357-1489CA32-95D1-4C31-98BD-2E808562AD84

Q37062357-148DD136-CB4E-4351-B597-6A43BFF661C1

Q37062357-23D073F9-AA46-40A3-BA2A-86F0214C0F85

Q37062357-2CA9B466-1DFF-4C8B-BC29-44F123CAF06F

Q37062357-3385D199-A195-4939-9A37-AD45540DC406

Q37062357-35ED9CB6-E7F3-4F62-919F-201390B47D60

Q37062357-46AC4700-415A-4EE5-B4F7-E7FC4E49D82E

Q37062357-6E06E35B-AB73-4F04-9502-E33B9B0F81F0

P304

Q37062357-5D808895-AE10-4423-BF87-E21C7FEEEA29

P31

Q37062357-C0F1A4AE-29C4-456A-91F4-8711DFE95C6E

P356

Q37062357-834F1C9E-A1D6-4F22-A5AD-541EB08952F0

P433

Q37062357-864B8C52-E836-45D0-A824-69C4C4232BC4

P478

Q37062357-689B989E-3C98-461C-908D-236FECD610C7

P577

Q37062357-636FD012-4C0E-45BD-9468-E9110768C45F

P698

Q37062357-F9601B2C-5F5C-4AC2-A1E4-7A977CC81F73

P932

Q37062357-084DC830-3733-40D7-8FA8-F509F4154C5D

P356

1940-6207.CAPR-13-0004

P1433

Cancer Prevention Research

P1476

Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial.

@en

P2093

Alexander Ross Kerr

http://www.w3.org/2001/XMLSchema#string

Anh D Le

http://www.w3.org/2001/XMLSchema#string

Ann R Kennedy

http://www.w3.org/2001/XMLSchema#string

Diana V Messadi

http://www.w3.org/2001/XMLSchema#string

Francisco Civantos

http://www.w3.org/2001/XMLSchema#string

Frank L Meyskens

http://www.w3.org/2001/XMLSchema#string

Lori J Wirth

http://www.w3.org/2001/XMLSchema#string

Mai Gu

http://www.w3.org/2001/XMLSchema#string

Marjorie Perloff

http://www.w3.org/2001/XMLSchema#string

Raymond J Melrose

http://www.w3.org/2001/XMLSchema#string

P2860

Notes from the field: "green" chemoprevention as frugal medicine

A follow-up study of sixty-one oral dysplastic precancerous lesions in Indian villagers

Soy, its components, and cancer prevention: a review of the in vitro, animal, and human data.

The Bowman-Birk inhibitor. Trypsin- and chymotrypsin-inhibitor from soybeans.

A serine protease activity in C3H/10T1/2 cells that is inhibited by anticarcinogenic protease inhibitors.

Development of the Bowman-Birk inhibitor for oral cancer chemoprevention and analysis of Neu immunohistochemical staining intensity with Bowman-Birk inhibitor concentrate treatment.

Soy intake and cancer risk: a review of the in vitro and in vivo data.

The c-erbB-2 protein in oncogenesis: molecular structure to molecular epidemiology.

Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer.

The c-erbB transmembrane growth factor receptors as serum biomarkers in human cancer studies.

P304

410-418

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1940-6207.CAPR-13-0004

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23639862

http://www.w3.org/2001/XMLSchema#string

P932

3730525

http://www.w3.org/2001/XMLSchema#string